Program
KXV01
A development code. Also written as “KXV01 TCR Lentinvivo Injection”.
Its studies are led by TCRx Therapeutics.
Furthest: phase 1, since Jul 22, 20253 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| TCRx Therapeutics | 33 open or running | phase 1since Jul 22, 2025 | Jul 22, 2025 | Dec 31, 2026phase 1 · NCT07196579 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 22, 2025First study: phase 1 study in Advanced Solid CancerFirst studyNCT07196579 · 30 planned · China
- Nov 27, 2025Phase 1 study in Advanced Solid TumorsNCT07275853 · 30 planned · China
- May 13, 2026Phase 1 study in Advanced Solid TumorsNCT07596693 · 30 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Advanced Solid TumorsNCT07275853
- Dec 31, 2026Primary completion: phase 1 study in Advanced Solid CancerNCT07196579
- Dec 31, 2027Primary completion: phase 1 study in Advanced Solid TumorsNCT07596693
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07596693Advanced Solid Tumors · China | 1 | Recruiting | Dec 31, 2027 | 30 |
| NCT07275853Advanced Solid Tumors · China | 1 | Recruiting | Dec 31, 2026 | 30 |
| NCT07196579Advanced Solid Cancer · China | 1 | Recruiting | Dec 31, 2026 | 30 |
How it is read
Names in the registry
- “KXV01 TCR Lentinvivo Injection”, 3 entries
Codes read as this program: KXV01.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.